View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 13, 2022

AbbVie reports data from Phase II large B-cell lymphoma therapy trial

The trial subjects had an overall response rate and complete response rate of 63% and 39%, respectively.

AbbVie has reported initial data from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 Phase II clinical trial of epcoritamab (DuoBody-CD3xCD20). 

Being developed jointly by AbbVie and Genmab under an oncology partnership, epcoritamab is an investigational subcutaneous IgG1-bispecific antibody. 

The multicentre, open-label EPCORE NHL-1 trial is designed to analyse the safety and preliminary efficacy of the antibody with a Phase I dose-escalation part, a Phase II expansion part and an optimisation part. 

It is analysing subcutaneous dose of epcoritamab in subjects with relapsed, progressive or refractory CD20+ mature B-non-Hodgkin’s lymphoma (B-NHL), including LBCL and diffuse large B-cell lymphoma (DLBCL), an LBCL subtype.

The study arm had 157 subjects with relapsed/refractory LBCL, who received a median of three lines of therapy earlier.

According to the findings, epcoritamab showed lasting responses in subjects who have priorly received a minimum of two lines of anti-lymphoma therapy including chimeric antigen receptor (CAR) T-cell therapy. 

Furthermore, the patients had an overall response rate (ORR) and complete response (CR) rate of 63% and 39%, respectively.

The trial subjects who were CAR T-cell therapy- naïve had an ORR and CR of 69% and 42%, respectively, and subjects who were previously treated with CAR T-cell therapy had a 54% ORR and a 34% CR. 

The median duration of response (mDOR) was reported to be 12 months following up to 10.7 months of median follow up but the mDOR in subjects who achieved a CR was not reached, with 89% remaining in CR at nine months. 

In the trial, epcoritamab’s safety profile was in line with prior data. 

AbbVie global oncology development vice-president and head Mohamed Zaki said: “The epcoritamab data suggests a potentially compelling clinical profile for patients with relapsed/refractory LBCL, which currently have limited treatment options. 

“Our partnership with Genmab allows us to continue exploring new standards of care for patients with blood cancer.”

In April this year, the company reported positive data from the Phase II REFINE trial of navitoclax with ruxolitinib for treating myelofibrosis.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena